Orgenesis Inc. Selling, General and Administrative (SG&A) Expenses Growth

Selling, General and Administrative (SG&A) Expenses Growth of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Selling, General and Administrative (SG&A) Expenses Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Selling, General and Administrative (SG&A) Expenses Growth for the quarter ending June 29, 2021 was -18.27% (a 6.78% increase compared to previous quarter)
  • Year-over-year quarterly Selling, General and Administrative (SG&A) Expenses Growth decreased by -127.47%
  • Annual Selling, General and Administrative (SG&A) Expenses Growth for 2020 was 116.6% (a -346.67% decrease from previous year)
  • Annual Selling, General and Administrative (SG&A) Expenses Growth for 2019 was -47.27% (a -Infinity% decrease from previous year)
  • Annual Selling, General and Administrative (SG&A) Expenses Growth for 2018 was 0.0% (a -100.0% decrease from previous year)
  • Twelve month Selling, General and Administrative (SG&A) Expenses Growth ending June 29, 2021 was 38.04% (a -27.8% decrease compared to previous quarter)
  • Twelve month trailing Selling, General and Administrative (SG&A) Expenses Growth decreased by -524.55% year-over-year
Trailing Selling, General and Administrative (SG&A) Expenses Growth for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
38.04% 52.69% 65.04% -8.96%
Visit stockrow.com/ORGS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Selling, General and Administrative (SG&A) Expenses Growth of Orgenesis Inc.

Most recent Selling, General and Administrative (SG&A) Expenses Growthof ORGS including historical data for past 10 years.

Interactive Chart of Selling, General and Administrative (SG&A) Expenses Growth of Orgenesis Inc.

Orgenesis Inc. Selling, General and Administrative (SG&A) Expenses Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -18.27% -17.11%
2020 138.33% 66.5% 28.58% 17.82% 116.6%
2019 -57.12% -39.82% -16.07% -10.71% -47.27%
2018 139.07% 64.8% 36.64% 47.25% 0.0%
2017 40.2% 91.5% 90.15% 77.56% 0.0%
2016 4.51% -41.56% 0.0%
2015 33.26%
2014 -24.45%
2013 0.0%
2012 49.57%

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.